<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869930</url>
  </required_header>
  <id_info>
    <org_study_id>NM101</org_study_id>
    <nct_id>NCT04869930</nct_id>
  </id_info>
  <brief_title>Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome</brief_title>
  <official_title>Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Mentis Life Science Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FourthWall Testing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Mentis Life Science Corp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to accumulate and quantitatively analyze data on the microbiome,&#xD;
      serotonin signaling and genetics, and inflammatory cytokines from patients with Autism&#xD;
      Spectrum Disorder and Fragile X Syndrome. Computational analysis of multi-dimensional&#xD;
      datasets will be used to establish a &quot;Diagnostic and Therapeutic Index&quot; - an objective set of&#xD;
      tools that can help differentiate subtypes of Autism Spectrum Disorder and develop more&#xD;
      accurate methods of diagnosis and response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>microbial diversity profile</measure>
    <time_frame>2 years</time_frame>
    <description>genetic analysis of microbial species in fecal samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences in serotonin levels</measure>
    <time_frame>2 years</time_frame>
    <description>molecular analysis of blood/urine/fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differential expression of serotonin-related signaling molecules</measure>
    <time_frame>2 years</time_frame>
    <description>genetic analysis of cheek swabs</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Fra(X) Syndrome</condition>
  <arm_group>
    <arm_group_label>Autism Spectrum Disorder (ASD)</arm_group_label>
    <description>Early childhood (pre-diagnosis) OR existing diagnosis of moderate/severe ASD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fragile X Syndrome (FXS)</arm_group_label>
    <description>Existing diagnosis of Fragile X Syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>No diagnosed chronic conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>specimen collection</intervention_name>
    <description>participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits</description>
    <arm_group_label>Autism Spectrum Disorder (ASD)</arm_group_label>
    <arm_group_label>Fragile X Syndrome (FXS)</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Autism Spectrum Disorder (ASD) and Fragile X Syndrome are neurodevelopmental disorders&#xD;
        characterized by repetitive behavioral patterns, hypersensitivity, and persistent deficits&#xD;
        in social communication. ASD is currently diagnosed exclusively on the basis of&#xD;
        neurobehavioral patterning - an approach that (1) cannot distinguish subtle differences&#xD;
        between ASD subtypes, (2) is subject to observer bias, and (3) introduces uncertainty&#xD;
        regarding root causes and response to treatments. Developmental disorders are often&#xD;
        accompanied by various co-occurring medical conditions like gastrointestinal dysfunction or&#xD;
        anemia, which can be leveraged to sub-segment the autisms spectrum and improve diagnostics&#xD;
        and treatment. Further investigation is needed to define the degree to which specific&#xD;
        comorbidities contribute to behavioral symptomology.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early childhood (pre-diagnosis) OR existing ASD diagnosis (Moderate to Severe)&#xD;
&#xD;
          -  Existing FXS diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalization&#xD;
&#xD;
          -  Enrolled in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia V Perederiy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Mentis Life Science Corp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia V Perederiy, PhD</last_name>
    <phone>888-505-NOVA</phone>
    <email>clinicaltrials@novamentis.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Mirer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

